Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SAT1 | P21673 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 5/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14980615 | 0.95 | CYP2C19 (0.43) | TSHRCYP2C19MEN1GLAKMT2A | |
| SCHEMBL1537292 | 0.91 | CYP2C19 (0.47) | TSHRCYP2C19MEN1GLAKMT2A | |
| SCHEMBL14980593 | 0.91 | CYP2C19 (0.40) | TSHRCYP2C19MEN1GLAKMT2A | |
| SCHEMBL23975243 | 0.90 | TSHR (0.42) | TSHRCYP2C19MEN1GLAKMT2A | |
| SCHEMBL758215 | 0.88 | TSHR (0.38) | TSHRCYP2C19MEN1GLAKMT2A | |
| Diethylamine SCHEMBL28268698 | 0.85 | TP53 (0.53) | TSHRCYP2C19MEN1GLAKMT2A | |
| SCHEMBL19844311 | 0.84 | TSHR (0.55) | TSHRCYP2C19MEN1GLAKMT2A | |
| SCHEMBL9597772 | 0.84 | TSHR (0.55) | TSHRCYP2C19MEN1GLAKMT2A | |
| SCHEMBL8347582 | 0.83 | ALDH1A1 (0.35) | TSHRCYP2C19HRH3 | |
| SCHEMBL8015726 | 0.83 | ALDH1A1 (0.35) | TSHRCYP2C19HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632903-B1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE | 2003-08-14 | — | — | US | disclosed |
| US-5618814-A | Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds | DR. KARL THOMAE GMBH (DE) | 1997-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153754-A1 | Fused pyrrolecarboxamides; a new class of GABA brain receptor ligands | GABRB1, GABRB3, GABRB2 | TSHR 166/4885CYP2C19 237/4885MEN1 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.